Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

April 2, 2021

Primary Completion Date

March 3, 2025

Study Completion Date

June 30, 2026

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

evorpacept

IV Q3W

DRUG

pembrolizumab

IV Q3W

Trial Locations (53)

1081

VUMC Goederenontvangst, Amsterdam

1200

Cliniques Universitaires Saint-Luc, Brussels

2146

St. Vincent's, Sydney

3051

Peter MacCallum Cancer Centre, Melbourne

3722

Severance Hospital Yonsei University, Seoul

4029

Royal Brisbane and Womens Hospital, Brisbane

5087

Ashford Cancer Centre Research, Windsor Gardens

6009

Sir Charles Gairdner Hospital, Perth

8500

AZ Groeninge, Kortrijk

9713

Universitair Medisch Centrum Groningen, Groningen

11101

Memorial Sloan-Kettering Cancer Center, Long Island City

13496

CHA University of Bundang, Gyeonggi-do

13620

Seoul National University Bundang Hospital, Seongnam

16247

Catholic University of Korea, St. Vincent's Hospital Suwon, Suwon

21201

University of Maryland Medical System, Baltimore

21565

Gachon University - Gil Medical Center, Incheon

26426

Yonsei University - Wonju Severance Christian Hospital, Wŏnju

28046

Hospital Universitario La Paz, Madrid

28050

HM Sanchinarro, Madrid

28644

Chungbuk National University Hospital, Cheongju-si

28911

Hospital Severo Ochoa, Madrid

29010

Hospital Regional Universitario de Malaga, Málaga

30060

Northwest Georgia Oncology Centers, Marietta

31008

Hospital Universitario de Navarra, Pamplona

33612

H. Lee Moffitt Cancer Center, Tampa

35015

Chungnam National University Hospital, Daejeon

37232

Vanderbilt - Ingram Cancer Center, Nashville

42415

Yeungnam University Medical Center, Daegu

43210

The Ohio State University, Columbus

60612

Rush University Medical Center, Chicago

62301

Blessing Cancer Center, Quincy

77030

Houston Methodist Cancer Center, Houston

92037

University of California San Diego, La Jolla

92618

Hoag Hospital, Irvine

97239

Oregon Health & Science University, Portland

119074

National University Cancer Institute, Singapore

169610

National Cancer Centre Singapore, Singapore

02114

Massachusetts General Hospital, Boston

07103

Rutgers Cancer Institute of New Jersey, Newark

B - 3000

UZ Leuven, Leuven

L9G2X1

Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton

N6A5W9

LHSC - Victoria Hospital, London

K1H 8L6

Ottawa Hospital Cancer Centre, Ottawa

Unknown

Princess Margaret Cancer Centre, Toronto

02841

Korea University Medical Center (KUMC) - Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

03312

The Catholic University of Korea - Eunpyeong St. Mary's Hospital, Seoul

06351

Samsung Medical Center, Seoul

07061

SNU Boramae Medical Center, Seoul

08028

Hospital Universitari Dexeus, Barcelona

08908

Institud Catala d´Oncologia, Barcelona

SW3 6JJ

Royal Marsden NHS Foundation Trust, London

SM2 5PT

Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

ALX Oncology Inc.

INDUSTRY

NCT04675294 - Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | Biotech Hunter | Biotech Hunter